About Fosun Kite
Kite and Fosun Pharma formed FosunKite in Shanghai China, a joint venture to develop, manufacture and commercialize axicabtagene ciloleucel in China with the option to include additional products, including two TCR product candidates from Kite.
This cooperation is a powerful combination of capital and technology.
Fosun Kite Biotechnology Co., Ltd. (hereinafter referred to as Fosun Kite) is a joint venture established by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Kite Pharma, Inc. (USA) in April 2017, Shanghai, China. Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients.
The company has obtained the comprehensive technology transfer and commercial license for Kite’s CAR-T product Axicabtagene Ciloleucel (US trade name Yescarta) in China. In accordance with Kite's commercial producing process and plant design concept, a clean cell preparation base graded as B+A that meets the current GMP standards has been built in Zhangjiang Hi-Tech Park. In addition to Yescarta, Fosun Kite's R&D pipeline includes CAR-T/TCR-T programs in clinical phase and innovative programs in early R&D phase.